ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
 PMID: 34897227       2022       Journal of acquired immune deficiency syndromes (1999)
Table: Y188C/H


  HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
 PMID: 34377002       2021       Infection and drug resistance
Table: Y188C/H/L


  HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
 PMID: 33668946       2021       Pathogens (Basel, Switzerland)
Result: Within a year, some minority DRMs at frequencies 1%-10% remained unchanged, including: PI-related D30N, M46LI, I54VT and N88D, NRTI-related K65R and NNRTI-related Y188CHL.


  HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
 PMID: 34762770       2021       Journal of the International AIDS Society
Table: Y188C/H


  HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.
 PMID: 32119691       2020       PloS one
Table: Y188L/H


  Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
 PMID: 32925358       2020       Journal of acquired immune deficiency syndromes (1999)
Introduction: This was followed by the emergence of Y188H/C or V179D and Y188C or L100I substitutions, respectively.
Discussion: In this NNRTI-experienced population (N = 6893), intermediate-level (defined as detection of any RT V106A/M, Y188C/H, V108I, and K103N + P225H substitution) and high-level (defined as detection of any RT Y188L, M230L, G190E, V106A/M + F227


  Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
 PMID: 32180823       2020       Drugs in context
Introduction: Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I,
Introduction: Other substitutions such as V106M, V108I, V179D, Y188H, or P236L conferred less than 10-FC against DOR.


  Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
 PMID: 32183889       2020       Virology journal
Result: The most frequent mutations to NNRTIs were K103N (41.90%), Y181C (28.12%), G190A (26.48%), K101E (11.71%), V106M/A (10.94%), V108I (7.44%), 221Y (7.22%) and Y188H (5.91%).The proportion of PI-associated DRMs showed a tendency to increase from 2012 to 2017(0, 0, 0.22, 0.98, 1.86 and 3.81%).
Table: Y188H


  HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.
 PMID: 32555643       2020       PloS one
Result: The prevalence of other major NNRTI resistance mutations (Y181CS, Y188CH, G190A and M230L) was <=8%.
Table: Y188H


  Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
 PMID: 32692778       2020       PloS one
Abstract: Fifteen (15) PDR mutations were found among four patients the urban settings [6 resistance mutations to NRTIs:[M41L (2), E44D (1), K65R (1), K70E (1), M184V/I (2), K219R (1)] and 6 resistance mutations to Result: In the two patients carrying resistance mutations in the samples from the rural setting, resistance mutations to only NNRTIs E138A (1) and Y188H (1)] were found.
Discussion: The mutation Y188YH (quasi-specie) found only in the rural setting renders an intermediate level of resistance to the first-line NNRTIs.



Browser Board

 Co-occurred Entities




   Filtrator